Approval for Xeltis’s aXess device was based on pivotal trial data that demonstrated 79% secondary patency and a patency-related reintervention rate of 1.3 per patient year.

Roche has reported new findings from the Phase III METEOROID trial of Enspryng in adults and adolescents with MOGAD.

At AAN 2026, Cabaletta Bio announced positive results from the Phase I/II open-label, RESET-MG study of rese-cel in patients with gMG.

At AAN 2026, Argenx announced positive results from the Phase III, double-blind, placebo-controlled, ADAPT SERON study of Vyvgart.

Currently in Phase I development, TherVacB is a therapeutic vaccine candidate designed as an immune therapy for chronic hepatitis B patients.

Novo Nordisk will be happy with the results after Pfizer has dropped two SCD assets in recent years. Credit: JHVEPhoto / Shutterstock.com A Phase III trial of Novo Nordisk’s once-daily tablet has met ...

AstraZeneca will submit the new COPD trial data to regulatory authorities. Credit: Robert Way / Shutterstock.com AstraZeneca’s tozorakimab has shown benefit in a third Phase III trial in chronic ...

Paradigm's SPIRE is designed to allow more routine care providers in community and rural settings to participate in post-marketing studies.

Agenus has reported results from a Phase II trial, evaluating the combination of BOT, BAL, and agenT-797 alongside ramucirumab and paclitaxel, in advanced PD-1 refractory gastroesophageal ...

Acerand Therapeutics has reported updated findings from its first-in-human Phase I/II study of ACE-106 to treat advanced solid tumours.

The FDA requires Eli Lilly to evaluate “unexpected serious” risks associated with Foundayo – some of which have been ...

Roche will be launching the Phase III trial to gain approval of Elevidys in Europe and other countries globally.